Compare PNNT & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PNNT | DERM |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.6M | 190.3M |
| IPO Year | 2007 | 2021 |
| Metric | PNNT | DERM |
|---|---|---|
| Price | $3.04 | $5.21 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | $4.75 | ★ $13.75 |
| AVG Volume (30 Days) | ★ 554.4K | 184.1K |
| Earning Date | 11-23-2026 | 11-11-2026 |
| Dividend Yield | ★ 15.95% | N/A |
| EPS Growth | N/A | ★ 34.72 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $61,858,000.00 |
| Revenue This Year | N/A | $25.29 |
| Revenue Next Year | $0.32 | $50.00 |
| P/E Ratio | $13.14 | ★ N/A |
| Revenue Growth | N/A | ★ 10.20 |
| 52 Week Low | $2.78 | $4.31 |
| 52 Week High | $6.58 | $9.56 |
| Indicator | PNNT | DERM |
|---|---|---|
| Relative Strength Index (RSI) | 44.26 | 40.61 |
| Support Level | $2.78 | $4.79 |
| Resistance Level | $3.89 | $5.50 |
| Average True Range (ATR) | 0.09 | 0.31 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 59.35 | 39.67 |
Pennant Park Investment Corp is a closed-end, non-diversified investment company. Its investment objective is to generate current income and capital appreciation also seeking to preserve capital through debt and equity investments. The company focuses on investing in United States middle-market companies that offer attractive risk-reward to investors and to create a diversified portfolio that includes senior secured debt, mezzanine debt, and equity investments. It generates majority of its revenue from interest and dividends received from investments made.
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.